{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:13:04Z","timestamp":1792815184591,"version":"4.5.0"},"reference-count":166,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Prince Sattam Bin Abdulaziz University Project Number","award":["PSAU\/2025\/R\/1447"],"award-info":[{"award-number":["PSAU\/2025\/R\/1447"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-026-04337-9","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T09:23:04Z","timestamp":1779182584000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["TIM-3 in AML: a janus-faced orchestrator of immune exhaustion and leukemic self-renewal"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1129-6930","authenticated-orcid":false,"given":"Ahmed","family":"Hjazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"issue":"1","key":"4337_CR1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s12672-025-01797-9","volume":"16","author":"U Ebinama","year":"2025","unstructured":"Ebinama U, George B. Revolutionizing acute myeloid leukemia treatment: a systematic review of immune-based therapies. Discover Oncol. 2025;16(1):89.","journal-title":"Discover Oncol"},{"issue":"1","key":"4337_CR2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40364-025-00738-6","volume":"13","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, et al. Unveiling the potential of CLL-1: a promising target for AML therapy. Biomark Res. 2025;13(1):28.","journal-title":"Biomark Res"},{"issue":"12","key":"4337_CR3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377.","journal-title":"Blood"},{"key":"4337_CR4","doi-asserted-by":"crossref","unstructured":"Lachowiez CA, DiNardo CD, Loghavi S. Molecularly Targeted Therapy in Acute Myeloid Leukemia: Current Treatment Landscape and Mechanisms of Response and Resistance. Cancers (Basel), 2023;15(5):1617","DOI":"10.3390\/cancers15051617"},{"issue":"1","key":"4337_CR5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41408-024-01186-5","volume":"14","author":"M Shahzad","year":"2024","unstructured":"Shahzad M, et al. What have we learned about TP53-mutated acute myeloid leukemia? Blood Cancer J. 2024;14(1):202.","journal-title":"Blood Cancer J"},{"key":"4337_CR6","unstructured":"Tripathi AK. Laboratory Evaluation of Acute Leukemia. StatPearls [Internet]; 2025."},{"issue":"6","key":"4337_CR7","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.stem.2010.11.014","volume":"7","author":"Y Kikushige","year":"2010","unstructured":"Kikushige Y, et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell. 2010;7(6):708\u201317.","journal-title":"Cell Stem Cell"},{"issue":"2","key":"4337_CR8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3324\/haematol.2022.280800","volume":"108","author":"P Stelmach","year":"2023","unstructured":"Stelmach P, Trumpp A. Leukemic stem cells and therapy resistance in acute myeloid leukemia. Haematologica. 2023;108(2):353\u201366.","journal-title":"Haematologica"},{"key":"4337_CR9","doi-asserted-by":"publisher","first-page":"102993","DOI":"10.1016\/j.critrevonc.2020.102993","volume":"152","author":"Y Tan","year":"2020","unstructured":"Tan Y, Wu Q, Zhou F. Targeting acute myeloid leukemia stem cells: Current therapies in development and potential strategies with new dimensions. Crit Rev Oncol\/Hematol. 2020;152:102993.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"5","key":"4337_CR10","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ajh.27625","volume":"100","author":"S Shimony","year":"2025","unstructured":"Shimony S, Stahl M, Stone RM. Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management. Am J Hematol. 2025;100(5):860\u201391.","journal-title":"Am J Hematol"},{"key":"4337_CR11","doi-asserted-by":"publisher","first-page":"100709","DOI":"10.1016\/j.blre.2020.100709","volume":"45","author":"JP Bewersdorf","year":"2021","unstructured":"Bewersdorf JP, Shallis RM, Zeidan AM. Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1\/PD-L1 and CTLA-4 pathways. Blood Rev. 2021;45:100709.","journal-title":"Blood Rev"},{"key":"4337_CR12","doi-asserted-by":"crossref","unstructured":"Liao D, et al. A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia. Frontiers in Pharmacology; 2019. pp. 10\u20132019.","DOI":"10.3389\/fphar.2019.00609"},{"issue":"1","key":"4337_CR13","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s10238-025-01795-9","volume":"25","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, et al. The AML immune paradox: decoding escape pathways and pioneering checkpoint, vaccine, and combination strategies. Clin Experimental Med. 2025;25(1):240.","journal-title":"Clin Experimental Med"},{"issue":"1","key":"4337_CR14","doi-asserted-by":"publisher","first-page":"2278229","DOI":"10.1080\/15384047.2023.2278229","volume":"24","author":"S Huang","year":"2023","unstructured":"Huang S, et al. Higher PD-1\/Tim-3 expression on IFN-\u03b3\u2009+\u2009T cells is associated with poor prognosis in patients with acute myeloid leukemia. Cancer Biol Ther. 2023;24(1):2278229.","journal-title":"Cancer Biol Ther"},{"issue":"4","key":"4337_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11912-019-0781-7","volume":"21","author":"M Stahl","year":"2019","unstructured":"Stahl M, Goldberg AD. Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets. Curr Oncol Rep. 2019;21(4):37.","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"4337_CR16","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1080\/10428194.2017.1344905","volume":"59","author":"P Boddu","year":"2018","unstructured":"Boddu P, et al. The emerging role of immune checkpoint based approaches in AML and MDS. Leuk Lymphoma. 2018;59(4):790\u2013802.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"4337_CR17","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","volume":"9","author":"N Daver","year":"2019","unstructured":"Daver N, et al. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed\/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov. 2019;9(3):370\u201383.","journal-title":"Cancer Discov"},{"issue":"2","key":"4337_CR18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1056\/NEJMoa1601202","volume":"375","author":"MS Davids","year":"2016","unstructured":"Davids MS, et al. Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016;375(2):143\u201353.","journal-title":"N Engl J Med"},{"issue":"9","key":"4337_CR19","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1182\/bloodadvances.2024015176","volume":"9","author":"AR Pyzer","year":"2025","unstructured":"Pyzer AR, et al. Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia. Blood Adv. 2025;9(9):2144\u201352.","journal-title":"Blood Adv"},{"issue":"6","key":"4337_CR20","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1038\/s41375-025-02566-x","volume":"39","author":"C Reinhardt","year":"2025","unstructured":"Reinhardt C, Ochsenbein AF. Immune checkpoints regulate acute myeloid leukemia stem cells. Leukemia. 2025;39(6):1277\u201393.","journal-title":"Leukemia"},{"issue":"2","key":"4337_CR21","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","volume":"57","author":"N Joller","year":"2024","unstructured":"Joller N, Anderson AC, Kuchroo VK. LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation. Immunity. 2024;57(2):206\u201322.","journal-title":"Immunity"},{"issue":"26","key":"4337_CR22","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1182\/blood.2023019961","volume":"143","author":"J Vadakekolathu","year":"2024","unstructured":"Vadakekolathu J, Rutella S. Escape from T-cell\u2013targeting immunotherapies in acute myeloid leukemia. Blood. 2024;143(26):2689\u2013700.","journal-title":"Blood"},{"issue":"6","key":"4337_CR23","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1007\/s00277-025-06387-x","volume":"104","author":"OS Aval","year":"2025","unstructured":"Aval OS, et al. Galectin-9: A double-edged sword in Acute Myeloid Leukemia. Ann Hematol. 2025;104(6):3077\u201390.","journal-title":"Ann Hematol"},{"issue":"1","key":"4337_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12885-024-11898-3","volume":"24","author":"H Shapourian","year":"2024","unstructured":"Shapourian H, et al. TIM-3\/Galectin-9 interaction and glutamine metabolism in AML cell lines, HL-60 and THP-1. BMC Cancer. 2024;24(1):125.","journal-title":"BMC Cancer"},{"key":"4337_CR25","doi-asserted-by":"crossref","unstructured":"Wang T et al. Galectins-1, -3 and \u2013\u20099 in leukemia: mechanistic insights and therapeutic translation. Front Immunol, 2025. Volume 16\u20132025.","DOI":"10.3389\/fimmu.2025.1685266"},{"issue":"1","key":"4337_CR26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s12013-014-9900-0","volume":"70","author":"L Gao","year":"2014","unstructured":"Gao L, Yu S, Zhang X. Hypothesis: Tim-3\/galectin-9, a new pathway for leukemia stem cells survival by promoting expansion of myeloid-derived suppressor cells and differentiating into tumor-associated macrophages. Cell Biochem Biophys. 2014;70(1):273\u20137.","journal-title":"Cell Biochem Biophys"},{"issue":"21","key":"4337_CR27","doi-asserted-by":"publisher","first-page":"4196","DOI":"10.1182\/blood.V122.21.4196.4196","volume":"122","author":"Y Kikushige","year":"2013","unstructured":"Kikushige Y, et al. TIM-3, a Leukemia Stem Cell Marker, Plays a Role In Leukemic Transformation Through Autocrine Stimulatory Signaling By Its Ligand, Galectin-9. Blood. 2013;122(21):4196\u20134196.","journal-title":"Blood"},{"issue":"6","key":"4337_CR28","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s12185-013-1433-6","volume":"98","author":"Y Kikushige","year":"2013","unstructured":"Kikushige Y, Miyamoto T. TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells. Int J Hematol. 2013;98(6):627\u201333.","journal-title":"Int J Hematol"},{"issue":"28","key":"4337_CR29","doi-asserted-by":"publisher","first-page":"eadw4871","DOI":"10.1126\/sciadv.adw4871","volume":"11","author":"G Gui","year":"2025","unstructured":"Gui G, et al. Single-cell spatial transcriptomics reveals immunotherapy-driven bone marrow niche remodeling in AML. Sci Adv. 2025;11(28):eadw4871.","journal-title":"Sci Adv"},{"issue":"11","key":"4337_CR30","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1038\/s41375-024-02381-w","volume":"38","author":"JB Koedijk","year":"2024","unstructured":"Koedijk JB, et al. A multidimensional analysis reveals distinct immune phenotypes and the composition of immune aggregates in pediatric acute myeloid leukemia. Leukemia. 2024;38(11):2332\u201343.","journal-title":"Leukemia"},{"key":"4337_CR31","doi-asserted-by":"publisher","first-page":"618710","DOI":"10.3389\/fimmu.2021.618710","volume":"12","author":"Z Wang","year":"2021","unstructured":"Wang Z, et al. One Stone, Two Birds: The Roles of Tim-3 in Acute Myeloid Leukemia. Front Immunol. 2021;12:618710.","journal-title":"Front Immunol"},{"key":"4337_CR32","doi-asserted-by":"publisher","first-page":"1627161","DOI":"10.3389\/fimmu.2025.1627161","volume":"16","author":"M Liu","year":"2025","unstructured":"Liu M, et al. Immunosuppressive cells in acute myeloid leukemia: mechanisms and therapeutic target. Front Immunol. 2025;16:1627161.","journal-title":"Front Immunol"},{"key":"4337_CR33","doi-asserted-by":"publisher","first-page":"10235","DOI":"10.3389\/ebm.2025.10235","volume":"250","author":"M Zhang","year":"2025","unstructured":"Zhang M, et al. Bone marrow immune cells and drug resistance in acute myeloid leukemia. Exp Biol Med (Maywood). 2025;250:10235.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"10","key":"4337_CR34","doi-asserted-by":"publisher","first-page":"e0140694","DOI":"10.1371\/journal.pone.0140694","volume":"10","author":"B Tomkowicz","year":"2015","unstructured":"Tomkowicz B, et al. TIM-3 Suppresses Anti-CD3\/CD28-Induced TCR Activation and IL-2 Expression through the NFAT Signaling Pathway. PLoS ONE. 2015;10(10):e0140694.","journal-title":"PLoS ONE"},{"key":"4337_CR35","doi-asserted-by":"crossref","unstructured":"Zhu C et al. Tim-3 adaptor protein Bat3 is a molecular checkpoint of T cell terminal differentiation and exhaustion. Sci Adv. 2021;7(18):eabd2710.","DOI":"10.1126\/sciadv.abd2710"},{"issue":"2","key":"4337_CR36","first-page":"216","volume":"8","author":"X Xu","year":"2024","unstructured":"Xu X, et al. FHL2 determines poor outcomes and responsiveness of immunotherapy plus tyrosine kinase Inhibition in metastatic renal cell carcinoma. Eurasian J Med Oncol. 2024;8(2):216.","journal-title":"Eurasian J Med Oncol"},{"issue":"16","key":"4337_CR37","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1016\/j.cell.2024.07.016","volume":"187","author":"LP Andrews","year":"2024","unstructured":"Andrews LP, et al. LAG-3 and PD-1 synergize on CD8\u2009+\u2009T cells to drive T cell exhaustion and hinder autocrine IFN-\u03b3-dependent anti-tumor immunity. Cell. 2024;187(16):4355\u2013e437222.","journal-title":"Cell"},{"issue":"1","key":"4337_CR38","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/s41467-021-21099-2","volume":"12","author":"R Yang","year":"2021","unstructured":"Yang R, et al. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat Commun. 2021;12(1):832.","journal-title":"Nat Commun"},{"issue":"17","key":"4337_CR39","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1042\/BCJ20210425","volume":"478","author":"CM Smith","year":"2021","unstructured":"Smith CM, et al. Phosphatidylserine binding directly regulates TIM-3 function. Biochem J. 2021;478(17):3331\u201349.","journal-title":"Biochem J"},{"issue":"1","key":"4337_CR40","doi-asserted-by":"publisher","first-page":"13579","DOI":"10.1038\/s41598-017-14064-x","volume":"7","author":"JK Weber","year":"2017","unstructured":"Weber JK, Zhou R. Phosphatidylserine-Induced Conformational Modulation of Immune Cell Exhaustion-Associated Receptor TIM3. Sci Rep. 2017;7(1):13579.","journal-title":"Sci Rep"},{"issue":"9","key":"4337_CR41","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/ni.2376","volume":"13","author":"S Chiba","year":"2012","unstructured":"Chiba S, et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol. 2012;13(9):832\u201342.","journal-title":"Nat Immunol"},{"issue":"69","key":"4337_CR42","doi-asserted-by":"publisher","first-page":"eabm0631","DOI":"10.1126\/sciimmunol.abm0631","volume":"7","author":"R Tang","year":"2022","unstructured":"Tang R, et al. Tim-3 adapter protein Bat3 acts as an endogenous regulator of tolerogenic dendritic cell function. Sci Immunol. 2022;7(69):eabm0631.","journal-title":"Sci Immunol"},{"issue":"1","key":"4337_CR43","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","volume":"8","author":"S Chen","year":"2023","unstructured":"Chen S, et al. Macrophages in immunoregulation and therapeutics. Signal Transduct Target Therapy. 2023;8(1):207.","journal-title":"Signal Transduct Target Therapy"},{"key":"4337_CR44","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3389\/fimmu.2016.00229","volume":"7","author":"R Oca\u00f1a-Guzman","year":"2016","unstructured":"Oca\u00f1a-Guzman R, Torre-Bouscoulet L, Sada-Ovalle I. TIM-3 Regulates Distinct Functions in Macrophages. Front Immunol. 2016;7:229.","journal-title":"Front Immunol"},{"key":"4337_CR45","doi-asserted-by":"publisher","first-page":"770402","DOI":"10.3389\/fimmu.2021.770402","volume":"12","author":"L Tang","year":"2021","unstructured":"Tang L, et al. Tim-3 Relieves Experimental Autoimmune Encephalomyelitis by Suppressing MHC-II. Front Immunol. 2021;12:770402.","journal-title":"Front Immunol"},{"issue":"1","key":"4337_CR46","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41392-024-02005-w","volume":"9","author":"S Chen","year":"2024","unstructured":"Chen S, Zhu H, Jounaidi Y. Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization. Signal Transduct Target Therapy. 2024;9(1):302.","journal-title":"Signal Transduct Target Therapy"},{"issue":"12","key":"4337_CR47","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.3390\/biomedicines12122717","volume":"12","author":"K Sun","year":"2024","unstructured":"Sun K, et al. The Functional Role and Prognostic Significance of TIM-3 Expression on NK Cells in the Diagnostic Bone Marrows in Acute Myeloid Leukemia. Biomedicines. 2024;12(12):2717.","journal-title":"Biomedicines"},{"key":"4337_CR48","doi-asserted-by":"publisher","first-page":"107458","DOI":"10.1016\/j.phrs.2024.107458","volume":"209","author":"J Zhang","year":"2024","unstructured":"Zhang J, et al. The role of Tim-3 blockade in the tumor immune microenvironment beyond T cells. Pharmacol Res. 2024;209:107458.","journal-title":"Pharmacol Res"},{"issue":"1","key":"4337_CR49","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12865-020-00377-6","volume":"21","author":"MJ Lee","year":"2020","unstructured":"Lee MJ, et al. Association of TIM-3 expression with glucose metabolism in Jurkat T cells. BMC Immunol. 2020;21(1):48.","journal-title":"BMC Immunol"},{"key":"4337_CR50","doi-asserted-by":"crossref","unstructured":"Rezaei M et al. TIM-3\/Gal-9 interaction affects glucose and lipid metabolism in acute myeloid leukemia cell lines. Front Immunol, 2023. Volume 14\u20132023.","DOI":"10.3389\/fimmu.2023.1267578"},{"key":"4337_CR51","doi-asserted-by":"crossref","unstructured":"Zhang J et al. T cell immunoglobulin and mucin domain protein 3 inhibits glycolysis in RAW 264.7 macrophages through Hexokinase 2. Scand J Immunol. 2020;93(2) e12981.","DOI":"10.1111\/sji.12981"},{"issue":"6","key":"4337_CR52","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.immuni.2021.04.019","volume":"54","author":"M de Pulido","year":"2021","unstructured":"de Pulido M. The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake. Immunity. 2021;54(6):1154\u2013e11677.","journal-title":"Immunity"},{"issue":"7865","key":"4337_CR53","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41586-021-03626-9","volume":"595","author":"KO Dixon","year":"2021","unstructured":"Dixon KO, et al. TIM-3 restrains anti-tumour immunity by regulating inflammasome activation. Nature. 2021;595(7865):101\u20136.","journal-title":"Nature"},{"issue":"3","key":"4337_CR54","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.imbio.2019.03.001","volume":"224","author":"EC So","year":"2019","unstructured":"So EC, et al. NK cell expression of Tim-3: First impressions matter. Immunobiology. 2019;224(3):362\u201370.","journal-title":"Immunobiology"},{"issue":"Suppl 1","key":"4337_CR55","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000431062","volume":"89","author":"Y Kikushige","year":"2015","unstructured":"Kikushige Y, Miyamoto T. Identification of TIM-3 as a Leukemic Stem Cell Surface Molecule in Primary Acute Myeloid Leukemia. Oncology. 2015;89(Suppl 1):28\u201332.","journal-title":"Oncology"},{"issue":"3","key":"4337_CR56","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.stem.2015.07.011","volume":"17","author":"Y Kikushige","year":"2015","unstructured":"Kikushige Y, et al. A TIM-3\/Gal-9 Autocrine Stimulatory Loop Drives Self-Renewal of Human Myeloid Leukemia Stem Cells and Leukemic Progression. Cell Stem Cell. 2015;17(3):341\u201352.","journal-title":"Cell Stem Cell"},{"issue":"3","key":"4337_CR57","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/cas.16431","volume":"116","author":"T Sakoda","year":"2025","unstructured":"Sakoda T, et al. TIM-3 marks measurable residual leukemic stem cells responsible for relapse after allogeneic stem cell transplantation. Cancer Sci. 2025;116(3):698\u2013709.","journal-title":"Cancer Sci"},{"key":"4337_CR58","doi-asserted-by":"publisher","unstructured":"Hong J, et al. TIM-3 Expression Level on AML Blasts Correlates With Presence of Core Binding Factor Translocations Rather Than Clinical Outcomes. Front Oncol. 2022;12. https:\/\/doi.org\/10.3389\/fonc.2022.879471.","DOI":"10.3389\/fonc.2022.879471"},{"issue":"11","key":"4337_CR59","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.3390\/biomedicines13112841","volume":"13","author":"Z-Y Shi","year":"2025","unstructured":"Shi Z-Y, et al. TIM-3 Promotes Proliferation of Acute Myeloid Leukemia Blasts. Biomedicines. 2025;13(11):2841.","journal-title":"Biomedicines"},{"issue":"60","key":"4337_CR60","doi-asserted-by":"publisher","first-page":"102088","DOI":"10.18632\/oncotarget.22141","volume":"8","author":"L Xu","year":"2017","unstructured":"Xu L, et al. High Tim-3 expression on AML blasts could enhance chemotherapy sensitivity. Oncotarget. 2017;8(60):102088\u201396.","journal-title":"Oncotarget"},{"issue":"12","key":"4337_CR61","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/ni1271","volume":"6","author":"C Zhu","year":"2005","unstructured":"Zhu C, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6(12):1245\u201352.","journal-title":"Nat Immunol"},{"issue":"1","key":"4337_CR62","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/s41420-023-01515-w","volume":"9","author":"G Choukrani","year":"2023","unstructured":"Choukrani G, et al. Galectin-9 has non-apoptotic cytotoxic activity toward acute myeloid leukemia independent of cytarabine resistance. Cell Death Discovery. 2023;9(1):228.","journal-title":"Cell Death Discovery"},{"issue":"14","key":"4337_CR63","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.7150\/jca.53686","volume":"12","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, et al. Galectin-9 and PSMB8 overexpression predict unfavorable prognosis in patients with AML. J Cancer. 2021;12(14):4257\u201363.","journal-title":"J Cancer"},{"issue":"1","key":"4337_CR64","doi-asserted-by":"publisher","first-page":"17512","DOI":"10.1038\/s41598-018-35754-0","volume":"8","author":"AK Gandhi","year":"2018","unstructured":"Gandhi AK, et al. High resolution X-ray and NMR structural study of human T-cell immunoglobulin and mucin domain containing protein-3. Sci Rep. 2018;8(1):17512.","journal-title":"Sci Rep"},{"issue":"2","key":"4337_CR65","doi-asserted-by":"publisher","first-page":"e1385690","DOI":"10.1080\/2162402X.2017.1385690","volume":"7","author":"CA Sabatos-Peyton","year":"2018","unstructured":"Sabatos-Peyton CA, et al. Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy. Oncoimmunology. 2018;7(2):e1385690.","journal-title":"Oncoimmunology"},{"key":"4337_CR66","doi-asserted-by":"crossref","unstructured":"Ma S et al. Identification of a small-molecule Tim-3 inhibitor to potentiate T cell\u2013mediated antitumor immunotherapy in preclinical mouse models. Sci Transl Med. 2023;15(722):eadg6752.","DOI":"10.1126\/scitranslmed.adg6752"},{"issue":"8","key":"4337_CR67","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1002\/eji.201948400","volume":"50","author":"S De Linhares","year":"2020","unstructured":"De Linhares S. TIM-3 and CEACAM1 do not interact in cis and in trans. Eur J Immunol. 2020;50(8):1126\u201341.","journal-title":"Eur J Immunol"},{"issue":"7534","key":"4337_CR68","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/nature13848","volume":"517","author":"YH Huang","year":"2015","unstructured":"Huang YH, et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature. 2015;517(7534):386\u201390.","journal-title":"Nature"},{"key":"4337_CR69","doi-asserted-by":"publisher","unstructured":"Jinushi M, Baghdadi M, Yagita H. Cross-talks of tumor and myeloid cells regulate the therapeutic responses to chemotherapy by modulating innate immune responses. J Immunother Cancer. 2013;1(Suppl 1):O16. https:\/\/doi.org\/10.1186\/2051-1426-1-S1-O16. eCollection 2013.","DOI":"10.1186\/2051-1426-1-S1-O16"},{"key":"4337_CR70","doi-asserted-by":"crossref","unstructured":"Shi ZY et al. Features and prognostic significance of soluble TIM-3 and its ligands Gal-9 and CEACAM1 levels in the diagnostic bone marrow of adult acute myeloid leukemia patients. J Leukoc Biol. 2024; 117(1):qiae191.","DOI":"10.1093\/jleuko\/qiae191"},{"issue":"9","key":"4337_CR71","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/nri3288","volume":"12","author":"GK Alderton","year":"2012","unstructured":"Alderton GK. TIM3 suppresses antitumour DCs. Nat Rev Immunol. 2012;12(9):621\u2013621.","journal-title":"Nat Rev Immunol"},{"key":"4337_CR72","doi-asserted-by":"crossref","unstructured":"Lv G et al. Multiple functions of HMGB1 in cancer. Front Oncol, 2024. Volume 14\u20132024.","DOI":"10.3389\/fonc.2024.1384109"},{"issue":"6","key":"4337_CR73","doi-asserted-by":"publisher","first-page":"e1438109","DOI":"10.1080\/2162402X.2018.1438109","volume":"7","author":"IM Yasinska","year":"2018","unstructured":"Yasinska IM, et al. High mobility group box 1 (HMGB1) acts as an alarmin to promote acute myeloid leukaemia progression. Oncoimmunology. 2018;7(6):e1438109.","journal-title":"Oncoimmunology"},{"issue":"1","key":"4337_CR74","doi-asserted-by":"publisher","first-page":"2278229","DOI":"10.1080\/15384047.2023.2278229","volume":"24","author":"S Huang","year":"2023","unstructured":"Huang S, et al. Higher PD-1\/Tim-3 expression on IFN-\u03b3\u2009+\u2009T cells is associated with poor prognosis in patients with acute myeloid leukemia. Cancer Biol Ther. 2023;24(1):2278229.","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"4337_CR75","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1007\/s00277-025-06418-7","volume":"104","author":"K Sun","year":"2025","unstructured":"Sun K, et al. The expression patterns and prognostic significance of PD-1 and TIM-3 on T cells and the differentiated subsets in acute myeloid leukemia. Ann Hematol. 2025;104(6):3235\u201350.","journal-title":"Ann Hematol"},{"issue":"1","key":"4337_CR76","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","volume":"33","author":"S Haubner","year":"2019","unstructured":"Haubner S, et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia. 2019;33(1):64\u201374.","journal-title":"Leukemia"},{"issue":"12","key":"4337_CR77","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1073\/pnas.1100551108","volume":"108","author":"M Jan","year":"2011","unstructured":"Jan M, et al. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci. 2011;108(12):5009\u201314.","journal-title":"Proc Natl Acad Sci"},{"issue":"10","key":"4337_CR78","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1182\/bloodadvances.2022008405","volume":"7","author":"T Sakoda","year":"2023","unstructured":"Sakoda T, et al. TIM-3 signaling hijacks the canonical Wnt\/\u03b2-catenin pathway to maintain cancer stemness in acute myeloid leukemia. Blood Adv. 2023;7(10):2053\u201365.","journal-title":"Blood Adv"},{"issue":"7","key":"4337_CR79","doi-asserted-by":"publisher","first-page":"8956","DOI":"10.1002\/cam4.5549","volume":"12","author":"Z Wu","year":"2023","unstructured":"Wu Z, et al. Upregulation of Tim-3 is associated with poor prognosis in acute myeloid leukemia. Cancer Med. 2023;12(7):8956\u201369.","journal-title":"Cancer Med"},{"issue":"Supplement 1","key":"4337_CR80","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1182\/blood-2023-180876","volume":"142","author":"R Zeiser","year":"2023","unstructured":"Zeiser R, et al. TIM-3 Inhibitor Sabatolimab for Patients with Acute Myeloid Leukemia (AML) with Measurable Residual Disease (MRD) Detected after Allogeneic Stem Cell Transplantation (AlloSCT): Preliminary Findings from the Phase Ib\/II Stimulus-AML2 Study. Blood. 2023;142(Supplement 1):59\u201359.","journal-title":"Blood"},{"key":"4337_CR81","doi-asserted-by":"publisher","first-page":"106873","DOI":"10.1016\/j.compbiomed.2023.106873","volume":"159","author":"M Zhu","year":"2023","unstructured":"Zhu M, et al. MLSpatial: a machine-learning method to reconstruct the spatial distribution of cells from scRNA-seq by extracting spatial features. Comput Biol Med. 2023;159:106873.","journal-title":"Comput Biol Med"},{"key":"4337_CR82","volume-title":"Innovative Medicine","author":"K Akashi","year":"2015","unstructured":"Akashi K. TIM-3 Is a Novel Therapeutic Target for Eradicating Acute Myelogenous Leukemia Stem Cells. Innovative Medicine. Tokyo: Springer Japan; 2015."},{"issue":"10","key":"4337_CR83","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s00277-012-1501-7","volume":"91","author":"K Hwang","year":"2012","unstructured":"Hwang K, et al. Flow cytometric quantification and immunophenotyping of leukemic stem cells in acute myeloid leukemia. Ann Hematol. 2012;91(10):1541\u20136.","journal-title":"Ann Hematol"},{"issue":"8","key":"4337_CR84","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1084\/jem.20151775","volume":"213","author":"L Quek","year":"2016","unstructured":"Quek L, et al. Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage. J Exp Med. 2016;213(8):1513\u201335.","journal-title":"J Exp Med"},{"issue":"7","key":"4337_CR85","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1182\/blood-2007-03-083048","volume":"110","author":"A van Rhenen","year":"2007","unstructured":"van Rhenen A, et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood. 2007;110(7):2659\u201366.","journal-title":"Blood"},{"issue":"8","key":"4337_CR86","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.clml.2021.03.009","volume":"21","author":"MMI Mohamed","year":"2021","unstructured":"Mohamed MMI, et al. Leukemic Stem Cell (CD34(+)\/CD38(-)\/TIM3(+)) Frequency in Patients with Acute Myeloid Leukemia: Clinical Implications. Clin Lymphoma Myeloma Leuk. 2021;21(8):508\u201313.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4337_CR87","doi-asserted-by":"crossref","unstructured":"Rezaei M et al. TIM-3 in Leukemia; Immune Response and Beyond. Front Oncol, 2021. Volume 11\u20132021.","DOI":"10.3389\/fonc.2021.753677"},{"key":"4337_CR88","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ebiom.2017.07.018","volume":"22","author":"I Gon\u00e7alves Silva","year":"2017","unstructured":"Gon\u00e7alves Silva I, et al. The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells. EBioMedicine. 2017;22:44\u201357.","journal-title":"EBioMedicine"},{"issue":"5","key":"4337_CR89","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.7150\/ijbs.92988","volume":"20","author":"W-X Xu","year":"2024","unstructured":"Xu W-X, et al. The burgeoning significance of liquid-liquid phase separation in the pathogenesis and therapeutics of cancers. Int J Biol Sci. 2024;20(5):1652.","journal-title":"Int J Biol Sci"},{"issue":"12","key":"4337_CR90","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","volume":"1","author":"BM Stevens","year":"2020","unstructured":"Stevens BM, et al. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nat Cancer. 2020;1(12):1176\u201387.","journal-title":"Nat Cancer"},{"issue":"6","key":"4337_CR91","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","volume":"13","author":"A Waclawiczek","year":"2023","unstructured":"Waclawiczek A, et al. Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine\/Venetoclax. Cancer Discov. 2023;13(6):1408\u201327.","journal-title":"Cancer Discov"},{"issue":"15","key":"4337_CR92","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1158\/0008-5472.CAN-23-1006","volume":"83","author":"E Griessinger","year":"2023","unstructured":"Griessinger E, et al. Oxidative Phosphorylation Fueled by Fatty Acid Oxidation Sensitizes Leukemic Stem Cells to Cold. Cancer Res. 2023;83(15):2461\u201370.","journal-title":"Cancer Res"},{"issue":"5","key":"4337_CR93","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/s41375-024-02208-8","volume":"38","author":"ES de Camargo Magalh\u00e3es","year":"2024","unstructured":"de Camargo Magalh\u00e3es ES, et al. Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapy. Leukemia. 2024;38(5):1046\u201356.","journal-title":"Leukemia"},{"issue":"1","key":"4337_CR94","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/proteomes13010011","volume":"13","author":"F Selheim","year":"2025","unstructured":"Selheim F, et al. Proteomic Comparison of Acute Myeloid Leukemia Cells and Normal CD34\u2009+\u2009Bone Marrow Cells: Studies of Leukemia Cell Differentiation and Regulation of Iron Metabolism\/Ferroptosis. Proteomes. 2025;13(1):11.","journal-title":"Proteomes"},{"issue":"1","key":"4337_CR95","doi-asserted-by":"publisher","first-page":"ltac019","DOI":"10.1093\/immadv\/ltac019","volume":"2","author":"S Schwartz","year":"2022","unstructured":"Schwartz S, et al. Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor. Immunother Adv. 2022;2(1):ltac019.","journal-title":"Immunother Adv"},{"issue":"2","key":"4337_CR96","doi-asserted-by":"publisher","first-page":"E32","DOI":"10.1002\/ajh.27161","volume":"99","author":"AM Brunner","year":"2024","unstructured":"Brunner AM, et al. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes. Am J Hematol. 2024;99(2):E32\u20136.","journal-title":"Am J Hematol"},{"issue":"1","key":"4337_CR97","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1016\/S2352-3026(23)00333-2","volume":"11","author":"AM Zeidan","year":"2024","unstructured":"Zeidan AM, et al. Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol. 2024;11(1):e38\u201350.","journal-title":"Lancet Haematol"},{"key":"4337_CR98","unstructured":"A Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) in Adult Patients Unfit for Chemotherapy. 2019."},{"key":"4337_CR99","unstructured":"A Phase Ib\/II, Open Label Study of Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual. Disease After Allogeneic Stem Cell Transplantation. 2020."},{"key":"4337_CR100","unstructured":"Amer M, Zeidan TK, Venditti A, Macias GR, Schuh A, Sanford D, Platzbecker U, Kim H-J, Westermann J\u00f6rg, Shenoy V, Lyu J, Menssen HD. Ludmila Lupu, Meryem Ktiouet Dawson, Jordi Esteve Reyner, PRIMARY RESULTS STIMULUS-AML1: A LARGE, INTERNATIONAL, PHASE II STUDY OF SABATOLIMAB COMBINED WITH AZACITIDINE AND VENETOCLAX AS FRONTLINE THERAPY FOR UNFIT ACUTE MYELOID LEUKEMIA (AML) PATIENTS (PTS). European Hematology Association; 2025."},{"key":"4337_CR101","doi-asserted-by":"publisher","first-page":"1374963","DOI":"10.3389\/fonc.2024.1374963","volume":"14","author":"S Bawek","year":"2024","unstructured":"Bawek S, et al. Updates in novel immunotherapeutic strategies for relapsed\/refractory AML. Front Oncol. 2024;14:1374963.","journal-title":"Front Oncol"},{"key":"4337_CR102","unstructured":"Randomized A., Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2). 2020."},{"key":"4337_CR103","unstructured":"A Phase 1, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of LB1410, A Recombinant Anti-PD-1 and Anti-TIM-3 Humanized Bispecific Antibody for Injection in Patients With Advanced Solid Tumors or Lymphoma(Keyplus-001). 2022."},{"key":"4337_CR104","volume-title":"\/II, Open, Dose-escalation and Expansion Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors","author":"A Phase Ib","year":"2024","unstructured":"Phase Ib A. \/II, Open, Dose-escalation and Expansion Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors, H. Shanghai East, Editor. 2024."},{"key":"4337_CR105","doi-asserted-by":"crossref","unstructured":"Acharya N, Sabatos-Peyton C, Anderson AC. Tim-3 finds its place in the cancer immunotherapy landscape. J Immunother Cancer. 2020;8(1):e000911","DOI":"10.1136\/jitc-2020-000911"},{"key":"4337_CR106","unstructured":"A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER). 2016."},{"key":"4337_CR107","doi-asserted-by":"crossref","unstructured":"Murtaza A et al. Discovery of TSR-022, a novel, potent anti-human TIM-3 therapeutic antibody. Eur J Cancer. 2016;69:32902-11","DOI":"10.1016\/S0959-8049(16)32903-3"},{"key":"4337_CR108","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1200\/JCO.2025.43.16_suppl.2586","volume":"43","author":"J Liu","year":"2025","unstructured":"Liu J, Zhou C. Phase 1 study of LB1410, a bivalent TIM-3\/PD-1 bispecific antibody, in patients with advanced solid tumors or lymphoma. J Clin Oncol. 2025;43:2586\u20132586.","journal-title":"J Clin Oncol"},{"issue":"9","key":"4337_CR109","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1182\/bloodadvances.2023011858","volume":"8","author":"Z Zeng","year":"2024","unstructured":"Zeng Z, et al. Dual-targeting CD33\/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile. Blood Adv. 2024;8(9):2059\u201373.","journal-title":"Blood Adv"},{"key":"4337_CR110","doi-asserted-by":"publisher","first-page":"100751","DOI":"10.1016\/j.omto.2023.100751","volume":"31","author":"JC Boucher","year":"2023","unstructured":"Boucher JC, et al. Bispecific CD33\/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Mol Therapy - Oncolytics. 2023;31:100751.","journal-title":"Mol Therapy - Oncolytics"},{"issue":"6","key":"4337_CR111","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s11899-018-0472-8","volume":"13","author":"DG Guy","year":"2018","unstructured":"Guy DG, Uy GL. Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia. Curr Hematol Malig Rep. 2018;13(6):417\u201325.","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"4337_CR112","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10238-025-01764-2","volume":"25","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, et al. Targeting acute myeloid leukemia through antibody engineering: innovations in immunotherapy and combination regimens. Clin Experimental Med. 2025;25(1):215.","journal-title":"Clin Experimental Med"},{"key":"4337_CR113","doi-asserted-by":"crossref","unstructured":"Falchook GS et al. Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER). J Clin Oncol. 2022;40(16_suppl):2504\u20132504.","DOI":"10.1200\/JCO.2022.40.16_suppl.2504"},{"key":"4337_CR114","doi-asserted-by":"publisher","first-page":"S255","DOI":"10.1016\/S2152-2650(22)01303-9","volume":"22","author":"AM Zeidan","year":"2022","unstructured":"Zeidan AM, et al. AML-484 First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab\u2009+\u2009Azacitidine\u2009+\u2009Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML). Clin Lymphoma Myeloma Leuk. 2022;22:S255.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"16","key":"4337_CR115","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1158\/1078-0432.CCR-25-0806","volume":"31","author":"D Davar","year":"2025","unstructured":"Davar D, et al. Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2B. Clin Cancer Res. 2025;31(16):3443\u201351.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"4337_CR116","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1182\/blood.2019002779","volume":"135","author":"X He","year":"2020","unstructured":"He X, et al. Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. Blood. 2020;135(10):713\u201323.","journal-title":"Blood"},{"issue":"9","key":"4337_CR117","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1158\/1535-7163.MCT-20-0155","volume":"20","author":"WS Lee","year":"2021","unstructured":"Lee WS, et al. Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells. Mol Cancer Ther. 2021;20(9):1702\u201312.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"4337_CR118","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s12935-023-03153-9","volume":"23","author":"P Klaihmon","year":"2023","unstructured":"Klaihmon P, et al. Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells. Cancer Cell Int. 2023;23(1):297.","journal-title":"Cancer Cell Int"},{"issue":"9","key":"4337_CR119","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1158\/1535-7163.MCT-20-0155","volume":"20","author":"W-HS Lee","year":"2021","unstructured":"Lee W-HS, et al. Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells. Mol Cancer Ther. 2021;20(9):1702\u201312.","journal-title":"Mol Cancer Ther"},{"issue":"Supplement 1","key":"4337_CR120","doi-asserted-by":"publisher","first-page":"4795","DOI":"10.1182\/blood-2024-206777","volume":"144","author":"X Chai","year":"2024","unstructured":"Chai X, et al. Split CAR-T Cells Targeting CD312 and TIM-3 for AML to Reduce the Risk of Antigen Escape. Blood. 2024;144(Supplement 1):4795\u20134795.","journal-title":"Blood"},{"issue":"11","key":"4337_CR121","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1007\/s00262-023-03516-1","volume":"72","author":"N Sauer","year":"2023","unstructured":"Sauer N, et al. TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors. Cancer Immunol Immunother. 2023;72(11):3405\u201325.","journal-title":"Cancer Immunol Immunother"},{"key":"4337_CR122","doi-asserted-by":"publisher","first-page":"113392","DOI":"10.1016\/j.intimp.2024.113392","volume":"144","author":"D-Y Sun","year":"2025","unstructured":"Sun D-Y, et al. Unlocking the full potential of memory T cells in adoptive T cell therapy for hematologic malignancies. Int Immunopharmacol. 2025;144:113392.","journal-title":"Int Immunopharmacol"},{"key":"4337_CR123","doi-asserted-by":"publisher","first-page":"S255","DOI":"10.1016\/S2152-2650(22)01303-9","volume":"22","author":"AM Zeidan","year":"2022","unstructured":"Zeidan AM, et al. AML-484 First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab\u2009+\u2009Azacitidine\u2009+\u2009Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML). Clin Lymphoma Myeloma Leuk. 2022;22:S255.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"22","key":"4337_CR124","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1042\/BCJ20210652","volume":"478","author":"LP Kane","year":"2021","unstructured":"Kane LP. Regulation of Tim-3 function by binding to phosphatidylserine. Biochem J. 2021;478(22):3999\u20134004.","journal-title":"Biochem J"},{"key":"4337_CR125","doi-asserted-by":"crossref","unstructured":"Wong KK, Hassan R, Yaacob NS. Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Front Oncol, 2021. Volume 11\u20132021.","DOI":"10.3389\/fonc.2021.624742"},{"issue":"4","key":"4337_CR126","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/bjh.15818","volume":"185","author":"MR Nahas","year":"2019","unstructured":"Nahas MR, et al. Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell\/AML vaccine. Br J Haematol. 2019;185(4):679\u201390.","journal-title":"Br J Haematol"},{"issue":"11","key":"4337_CR127","doi-asserted-by":"publisher","first-page":"12840","DOI":"10.18632\/oncotarget.7326","volume":"7","author":"P Srivastava","year":"2016","unstructured":"Srivastava P, et al. Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. Oncotarget. 2016;7(11):12840\u201356.","journal-title":"Oncotarget"},{"issue":"6","key":"4337_CR128","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41419-024-06810-7","volume":"15","author":"GO Nwosu","year":"2024","unstructured":"Nwosu GO, et al. Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia. Cell Death Dis. 2024;15(6):413.","journal-title":"Cell Death Dis"},{"issue":"2","key":"4337_CR129","doi-asserted-by":"publisher","first-page":"380","DOI":"10.20517\/cdr.2021.125","volume":"5","author":"F Ong","year":"2022","unstructured":"Ong F, Kim K, Konopleva MY. Venetoclax resistance: mechanistic insights and future strategies. Cancer Drug Resist. 2022;5(2):380\u2013400.","journal-title":"Cancer Drug Resist"},{"issue":"7","key":"4337_CR130","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","volume":"35","author":"N Daver","year":"2021","unstructured":"Daver N, et al. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia. 2021;35(7):1843\u201363.","journal-title":"Leukemia"},{"issue":"1","key":"4337_CR131","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s43556-025-00267-6","volume":"6","author":"Z Yan","year":"2025","unstructured":"Yan Z, et al. TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives. Mol Biomed. 2025;6(1):27.","journal-title":"Mol Biomed"},{"key":"4337_CR132","doi-asserted-by":"publisher","first-page":"1751463","DOI":"10.3389\/fimmu.2026.1751463","volume":"17","author":"S Dong","year":"2026","unstructured":"Dong S, et al. Experimental study on synergistic pulses improving the tumor microenvironment and assisting immunotherapy. Front Immunol. 2026;17:1751463.","journal-title":"Front Immunol"},{"issue":"2","key":"4337_CR133","doi-asserted-by":"publisher","first-page":"108557","DOI":"10.1016\/j.cclet.2023.108557","volume":"35","author":"L Guo","year":"2024","unstructured":"Guo L, Ding J, Zhou W. Harnessing bacteria for tumor therapy: current advances and challenges. Chin Chem Lett. 2024;35(2):108557.","journal-title":"Chin Chem Lett"},{"issue":"1","key":"4337_CR134","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/imm.13793","volume":"173","author":"ZB Wang","year":"2024","unstructured":"Wang ZB, et al. Immunotherapy and the ovarian cancer microenvironment: exploring potential strategies for enhanced treatment efficacy. Immunology. 2024;173(1):14\u201332.","journal-title":"Immunology"},{"issue":"51","key":"4337_CR135","doi-asserted-by":"publisher","first-page":"88904","DOI":"10.18632\/oncotarget.21492","volume":"8","author":"T Asayama","year":"2017","unstructured":"Asayama T, et al. Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes. Oncotarget. 2017;8(51):88904\u201317.","journal-title":"Oncotarget"},{"issue":"1","key":"4337_CR136","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/diseases13010019","volume":"13","author":"GP Barakos","year":"2025","unstructured":"Barakos GP, et al. Elucidating the Role of the T Cell Receptor Repertoire in Myelodysplastic Neoplasms and Acute Myeloid Leukemia. Diseases. 2025;13(1):19.","journal-title":"Diseases"},{"issue":"11","key":"4337_CR137","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1182\/blood.2025031480","volume":"147","author":"J Cloos","year":"2026","unstructured":"Cloos J, et al. 2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party. Blood. 2026;147(11):1147\u201367.","journal-title":"Blood"},{"key":"4337_CR138","doi-asserted-by":"crossref","unstructured":"Heuser M et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood, 2021. 138(26): pp. 2753\u20132767.","DOI":"10.1182\/blood.2021013626"},{"issue":"20","key":"4337_CR139","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1182\/bloodadvances.2020002512","volume":"4","author":"J Vadakekolathu","year":"2020","unstructured":"Vadakekolathu J, et al. TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. Blood Adv. 2020;4(20):5011\u201324.","journal-title":"Blood Adv"},{"issue":"1","key":"4337_CR140","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-024-02212-7","volume":"24","author":"BH Alsaafeen","year":"2025","unstructured":"Alsaafeen BH, Ali BR, Elkord E. Resistance mechanisms to immune checkpoint inhibitors: updated insights. Mol Cancer. 2025;24(1):20.","journal-title":"Mol Cancer"},{"issue":"1","key":"4337_CR141","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s43556-025-00267-6","volume":"6","author":"Z Yan","year":"2025","unstructured":"Yan Z, et al. TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives. Mol Biomed. 2025;6(1):27.","journal-title":"Mol Biomed"},{"issue":"94","key":"4337_CR142","doi-asserted-by":"publisher","first-page":"20140079","DOI":"10.1098\/rsif.2014.0079","volume":"11","author":"T Stiehl","year":"2014","unstructured":"Stiehl T, et al. Clonal selection and therapy resistance in acute leukaemias: mathematical modelling explains different proliferation patterns at diagnosis and relapse. J R Soc Interface. 2014;11(94):20140079.","journal-title":"J R Soc Interface"},{"key":"4337_CR143","doi-asserted-by":"crossref","unstructured":"Guo C et al. In situ extended immune activation instantly after tumor resection by oncolytic virus controls postoperative tumor recurrence. Cell Rep Med. 2025;6(10):1-12","DOI":"10.1016\/j.xcrm.2025.102399"},{"issue":"6","key":"4337_CR144","doi-asserted-by":"publisher","first-page":"e2857","DOI":"10.1038\/cddis.2017.249","volume":"8","author":"S Kasai","year":"2017","unstructured":"Kasai S, et al. Inflammatory mediator ultra-low-molecular-weight hyaluronan triggers necrosis of B-precursor leukemia cells with high surface CD44 expression. Cell Death Dis. 2017;8(6):e2857\u20132857.","journal-title":"Cell Death Dis"},{"key":"4337_CR145","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.3389\/fimmu.2019.01594","volume":"10","author":"IM Yasinska","year":"2019","unstructured":"Yasinska IM, et al. The Tim-3-Galectin-9 Pathway and Its Regulatory Mechanisms in Human Breast Cancer. Front Immunol. 2019;10:1594.","journal-title":"Front Immunol"},{"issue":"9","key":"4337_CR146","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1590\/S0100-879X2008000900002","volume":"41","author":"T Hu","year":"2008","unstructured":"Hu T, et al. Measurement of annexin V uptake and lactadherin labeling for the quantification of apoptosis in adherent Tca8113 and ACC-2 cells. Braz J Med Biol Res. 2008;41(9):750\u20137.","journal-title":"Braz J Med Biol Res"},{"issue":"5\u20136","key":"4337_CR147","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1006\/bcmd.1999.0254","volume":"25","author":"JF Tait","year":"1999","unstructured":"Tait JF, Smith C, Wood BL. Measurement of phosphatidylserine exposure in leukocytes and platelets by whole-blood flow cytometry with annexin V. Blood Cells Mol Dis. 1999;25(5\u20136):271\u20138.","journal-title":"Blood Cells Mol Dis"},{"issue":"1","key":"4337_CR148","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R","volume":"31","author":"M van Engeland","year":"1998","unstructured":"van Engeland M, et al. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry. 1998;31(1):1\u20139.","journal-title":"Cytometry"},{"issue":"9","key":"4337_CR149","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1158\/2159-8290.CD-15-0298","volume":"5","author":"GK Behbehani","year":"2015","unstructured":"Behbehani GK, et al. Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy. Cancer Discov. 2015;5(9):988\u20131003.","journal-title":"Cancer Discov"},{"key":"4337_CR150","doi-asserted-by":"publisher","unstructured":"Pilla L. Maccalli Immune Profiling of Cancer Patients Treated with Immunotherapy: Advances and Challenges. Biomedicines. 2018;6. https:\/\/doi.org\/10.3390\/biomedicines6030076.","DOI":"10.3390\/biomedicines6030076"},{"issue":"6","key":"4337_CR151","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","volume":"176","author":"P van Galen","year":"2019","unstructured":"van Galen P, et al. Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. Cell. 2019;176(6):1265\u2013e128124.","journal-title":"Cell"},{"key":"4337_CR152","doi-asserted-by":"crossref","unstructured":"Zhou J, Chng W-J. Unveiling novel insights in acute myeloid leukemia through single-cell RNA sequencing. Front Oncol, 2024. Volume 14\u20132024.","DOI":"10.3389\/fonc.2024.1365330"},{"issue":"1","key":"4337_CR153","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s10238-025-01783-z","volume":"25","author":"M Abdar Esfahani","year":"2025","unstructured":"Abdar Esfahani M, et al. The epigenetic revolution in hematology: from benchside breakthroughs to clinical transformations. Clin Experimental Med. 2025;25(1):230.","journal-title":"Clin Experimental Med"},{"issue":"31","key":"4337_CR154","doi-asserted-by":"publisher","first-page":"4893","DOI":"10.1200\/JCO.22.02604","volume":"41","author":"NG Daver","year":"2023","unstructured":"Daver NG, et al. Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results. J Clin Oncol. 2023;41(31):4893\u2013904.","journal-title":"J Clin Oncol"},{"key":"4337_CR155","doi-asserted-by":"crossref","unstructured":"Greiner J et al. Different immunotherapeutic combinations enhance specific T cell immune responses against leukemic cells, as well as leukemic progenitor cells, in acute myeloid leukemia. Leukemia. 2025;40(1):130-137","DOI":"10.1038\/s41375-025-02764-7"},{"key":"4337_CR156","doi-asserted-by":"publisher","first-page":"104916","DOI":"10.1016\/j.critrevonc.2025.104916","volume":"215","author":"M Huang","year":"2025","unstructured":"Huang M, et al. Epigenetic mechanisms and next-gen editing platforms in hematology: From molecular basis to therapeutic frontiers. Crit Rev Oncol\/Hematol. 2025;215:104916.","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"4337_CR157","doi-asserted-by":"crossref","unstructured":"Keshari S, Barrodia P, Singh AK. Epigenetic Perspective of Immunotherapy for Cancers. Cells, 2023. 12(3).p.365","DOI":"10.3390\/cells12030365"},{"key":"4337_CR158","doi-asserted-by":"crossref","unstructured":"Belsky MA, et al. Association of Mast Cell Burden and TIM-3 Expression with Recalcitrant Chronic Rhinosinusitis with Nasal Polyps. Volume 130. Annals of Otology, Rhinology & Laryngology; 2021. pp. 1069\u201377. 9.","DOI":"10.1177\/0003489421995038"},{"key":"4337_CR159","doi-asserted-by":"crossref","unstructured":"Dao TN et al. TIM-3 Expression Is Downregulated on Human NK Cells in Response to Cancer Targets in Synergy with Activation. Cancers (Basel). 2020;12(9):1-15","DOI":"10.3390\/cancers12092417"},{"key":"4337_CR160","doi-asserted-by":"crossref","unstructured":"Dixon KO, Lahore GF, Kuchroo VK. Beyond T cell exhaustion: TIM-3 regulation of myeloid cells. Sci Immunol . 2024;9(93):eadf2223.","DOI":"10.1126\/sciimmunol.adf2223"},{"issue":"1","key":"4337_CR161","doi-asserted-by":"publisher","first-page":"ltac021","DOI":"10.1093\/immadv\/ltac021","volume":"2","author":"S Barth","year":"2022","unstructured":"Barth S, Naran K. TIM-3: a tumor-associated antigen beyond checkpoint inhibition? Immunother Adv. 2022;2(1):ltac021.","journal-title":"Immunother Adv"},{"issue":"1","key":"4337_CR162","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai L, et al. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023;16(1):101.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"4337_CR163","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","volume":"9","author":"G Zhong","year":"2024","unstructured":"Zhong G, et al. Targeted protein degradation: advances in drug discovery and clinical practice. Signal Transduct Target Therapy. 2024;9(1):308.","journal-title":"Signal Transduct Target Therapy"},{"key":"4337_CR164","doi-asserted-by":"publisher","first-page":"129742","DOI":"10.1016\/j.bmcl.2024.129742","volume":"104","author":"Q Dai","year":"2024","unstructured":"Dai Q, et al. Discovery of novel nucleoside derivatives as selective lysine acetyltransferase p300 inhibitors for cancer therapy. Bioorg Med Chem Lett. 2024;104:129742.","journal-title":"Bioorg Med Chem Lett"},{"key":"4337_CR165","doi-asserted-by":"publisher","first-page":"1315283","DOI":"10.3389\/fimmu.2024.1315283","volume":"15","author":"BC Cianciotti","year":"2024","unstructured":"Cianciotti BC, et al. TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells. Front Immunol. 2024;15:1315283.","journal-title":"Front Immunol"},{"issue":"22","key":"4337_CR166","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1182\/blood.2024025440","volume":"145","author":"A Falg\u00e0s","year":"2025","unstructured":"Falg\u00e0s A, et al. A TIM-3-Fc decoy secreted by engineered T cells improves CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukemia. Blood. 2025;145(22):2599\u2013613.","journal-title":"Blood"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-026-04337-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04337-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04337-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T04:01:31Z","timestamp":1783915291000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12935-026-04337-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":166,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4337"],"URL":"https:\/\/doi.org\/10.1186\/s12935-026-04337-9","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"23 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"256"}}